Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia
Authors:
- Pellegrino MustoPMPellegrino Musto
- Giuseppe PietrantuonoGPGiuseppe Pietrantuono
- Roberto GuarigliaRGRoberto Guariglia
- Oreste VillaniOVOreste Villani
- Maria Carmen MartorelliMMMaria Carmen Martorelli
- Fiorella D’auriaFDFiorella D’auria
- Antonia ZonnoAZAntonia Zonno
- Rosa LeroseRLRosa Lerose
- 31 October 2008
- journal article
- other
- Published by Elsevier in Leukemia Research
- Vol. 32 (10) , 1637-1638
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma NetworkJournal of Clinical Oncology, 2007
- Efficacy and safety of bortezomib in patients with plasma cell leukemiaCancer, 2007
- Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single centerLeukemia & Lymphoma, 2007
- Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.Leukemia & Lymphoma, 2007
- Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem‐cell transplantation and review of the literatureAmerican Journal of Hematology, 2005
- Thalidomide in Low Doses is Effective for the Treatment of Resistant or Relapsed Multiple Myeloma and for Plasma Cell LeukaemiaLeukemia & Lymphoma, 2002
- Plasma cell leukemiaCurrent Treatment Options in Oncology, 2001